Trial Profile

A Phase 2b/3 registrational study in cystic fibrosis patients

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 21 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AP PA02 (Primary)
Indications Cystic fibrosis
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Armata Pharmaceuticals

Most Recent Events

15 Aug 2024 According to a Armata Pharmaceuticals media release, the company plans to initiate this trial in next year.
21 Aug 2023 New trial record
14 Aug 2023 According to a Armata Pharmaceuticals media release, a Phase 2b/3 registrational study in cystic fibrosis (CF) patients in planned in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com